https://cpi-169inhibitor.com/b....rand-new-model-regar
Eligibility for inclusion relied on a PDTC diagnosis in accordance with Turin criteria, supported by evidence of disease progression during the prior six months. Eight patients with PDTC received, on average, 181 mg of lenvatinib over a median treatment period of 103 months. The Eastern Cooperative Oncology Group performance status at baseline was two in fifty percent of the cases. Unresectable primary
Tycka om
Kommentar
Dela med sig
